Exclusive Summary

• Novel Target with Disease-Modifying Potential: Targeting RAGE, an upstream inflammation regulator, it breaks through the limitations of current symptomatic COPD treatments, offering a promising causal therapeutic pathway to actually retard disease progression.
• Innovative Inhaled Long-Acting siRNA Delivery: Precise pulmonary administration avoids or substantially minimizes systemic and renal toxicities, while a revolutionary long-acting Q2M (every two months) regiment elevates patient compliance.
• Excellent Preclinical Efficacy & Safety Profile: Showcases robust inhibition of RAGE expression and suppresses profound airway inflammatory infiltration in vivo, further boasting significantly verified low off-target risks through precise RNA sequencing.
• Optimal Early-Stage Global Partnering Asset: Steadily advancing through the IND-Enabling stage, laying out an advantageous window for global pharma to license-in a paradigm-shifting oligonucleotide candidate addressing the multi-billion-dollar respiratory unmet needs.

Asset Materials

Contact Us for Full Materials